Texas: The US Food and Drug Administration (USFDA) has approved Acer Therapeutics Inc's drug for treating patients with urea cycle disorders (UCDs), according to the health regulator's website.

The approval letter said the drug, sodium phenylbutyrate, could be used as an adjunctive therapy to the standard of care for patients with UCDs with certain deficiencies.

UCD is a genetic condition that causes toxic ammonia to build up in the blood due to the deficiency of certain enzymes.

The company resubmitted its marketing application for the drug in July after getting the so-called "complete response letter" from the USFDA in June.

The company did not immediately respond to a Reuters request for comment about the drug's pricing and availability.

USFDA gives approval for Lymphoma Therapy

USFDA gives approval for Pregabalin capsules

USFDA gives approval for Brivaracetam Tablets

USFDA approves Gene Therapy for Bladder Cance

USFDA approves this lung cancer drug

USFDA gives nod for Silodosin, Pregabalin Capsules

USFDA gives approval for Lymphoma Therapy

PCI directs State Pharmacy Councils to expedite transfer of registration of Pharmacist

300 life-saving drugs needed from Indian Pharma Cos: Saudi Arab

Registration for sale of Medical Devices: Procedure and conditions

NPPA fixes Retail Price of 10 formulations: December 2022

Drug recall: This Blood Pressure tablets recalled

NPPA fixes Retail Price of 12 scheduled formulations: December 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/25/usfda-gives-approval-for-this-genetic-disorder-drug/